The PennZone

  • Home
  • Non-profit
  • Health
  • Books
  • Business
  • Entertainment
  • Legal
  • Marketing
  • Financial

Coeptis Therapeutics Announces Reverse Stock Split
The PennZone/10291361

Trending...
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
WEXFORD, Pa., Dec. 27, 2024 ~ Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has announced its plans to proceed with a 1-for-20 reverse stock split of its issued and outstanding shares of common stock. The decision was made following authorization by the company's board of directors and majority stockholders to effect a reverse stock split by a ratio of not less than 1-for-3 and not more than 1-for-40.

The reverse stock split, also known as a consolidation, will see every 20 shares of the company's outstanding and issued common stock converted into one share. This move is intended to help Coeptis meet the minimum bid price requirement necessary to maintain its listing on the Nasdaq Capital Market. Under Nasdaq rules, listed companies must maintain a minimum bid price of at least $1.00 per share.

The decision to proceed with the reverse split was approved by Coeptis' stockholders at the company's Annual Stockholder's Meeting on December 18, 2024. Following this meeting, the Board established the reverse split ratio and authorized it to proceed.

More on The PennZone
  • Prolific Press Opens Full-Length Book Submissions for Poetry, Fiction and Non-Fiction
  • Clear Path Landscaping Announces Commercial and Residential Snow Removal for 2026-27 Season
  • Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show
  • Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
  • Scott Glickson Joins STS Capital Partners as Managing Director

The first day of trading on a post-split basis on the Nasdaq Capital Market will be at market open on December 31, 2024. Upon the effective date of the Reverse Split, any fractional shares for record holders that would have resulted from the split will be rounded up to the next whole number. This will not alter any stockholder's percentage interest in the Company's outstanding common stock, except for adjustments that may result from the treatment of fractional shares.

Continental Stock Transfer has been appointed as the exchange agent and transfer agent for the reverse stock split. They will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new ones if they wish to do so. However, those who hold their shares in brokerage accounts or "street name" are not required to take any action.

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases. Its subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. The company's product portfolio includes assets licensed from Deverra Therapeutics and the University of Pittsburgh. It is also developing a universal CAR technology in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institute.

More on The PennZone
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
  • PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence
  • 33,714 US social services nonprofits and the funding calls still open to them
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets

The Company's CEO expressed excitement about the potential of their innovative cell therapy platforms to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis is headquartered in Wexford, PA.

Investors are advised to exercise caution when considering any investment in Coeptis Therapeutics Holdings, Inc. as there are inherent risks associated with investing in biopharmaceutical companies. For more information on Coeptis and its developments, visit https://coeptistx.com.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
  • Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
  • Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
  • Angela's Boutique Highlights Self-Care Gifts for Philadelphia Holiday Shoppers
  • Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • Veteran Antiques Expert John Swahn Releases New Book: The Truth About Antiques
  • Steven Weisz of Art Imagined Photography to exhibit at ExpoMetro Florence, Italy
  • Hope Survives Managing Director Jasmine Balignasay-Chavez Receives 2026 Catalyst Award
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Kellyn Co-Founder Meagan Grega Named President-Elect of the American College of Lifestyle Medicine
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award

Popular on PennZone

  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs - 182
  • Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal - 174
  • WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client - 140
  • Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers" - 111
  • Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders - 103
  • Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers
  • Pastor Carlton L. Aiken Sr. Celebrates 55 Years with "Sermonic Selections"
  • No Bounds Digital Acquires Draidel's HubSpot Agency Business, Expanding Reach and Capabilities

Similar on PennZone

  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us